Your browser doesn't support javascript.
loading
Regional Variation in RBM20 Causes a Highly Penetrant Arrhythmogenic Cardiomyopathy.
Parikh, Victoria N; Caleshu, Colleen; Reuter, Chloe; Lazzeroni, Laura C; Ingles, Jodie; Garcia, John; McCaleb, Kristen; Adesiyun, Tolulope; Sedaghat-Hamedani, Farbod; Kumar, Saurabh; Graw, Sharon; Gigli, Marta; Stolfo, Davide; Dal Ferro, Matteo; Ing, Alexander Y; Nussbaum, Robert; Funke, Birgit; Wheeler, Matthew T; Hershberger, Ray E; Cook, Stuart; Steinmetz, Lars M; Lakdawala, Neal K; Taylor, Matthew R G; Mestroni, Luisa; Merlo, Marco; Sinagra, Gianfranco; Semsarian, Christopher; Meder, Benjamin; Judge, Daniel P; Ashley, Euan.
Afiliação
  • Parikh VN; Division of Cardiovascular Medicine, Department of Medicine (V.N.P., C.C., C.R., M.T.W., E.A.A.), Stanford University School of Medicine, CA.
  • Caleshu C; Division of Cardiovascular Medicine, Department of Medicine (V.N.P., C.C., C.R., M.T.W., E.A.A.), Stanford University School of Medicine, CA.
  • Reuter C; Division of Cardiovascular Medicine, Department of Medicine (V.N.P., C.C., C.R., M.T.W., E.A.A.), Stanford University School of Medicine, CA.
  • Lazzeroni LC; Department of Psychiatry and Behavioral Sciences (L.C.L.), Stanford University School of Medicine, CA.
  • Ingles J; Department of Biomedical Data Science (L.C.L.), Stanford University School of Medicine, CA.
  • Garcia J; Department of Cardiology, Royal Prince Alfred Hospital and Agnes Ginges Centre for Molecular Cardiology, Centenary Institute, University of Sydney, New South Wales, Australia (J.I., C.S.).
  • McCaleb K; Invitae, Inc, San Francisco, CA (J.G., R.N.).
  • Adesiyun T; Genomic Health, Inc, Redwood City, CA (K.M.).
  • Sedaghat-Hamedani F; Johns Hopkins School of Medicine, Baltimore, MD (T.A.).
  • Kumar S; Institute for Cardiomyopathies, University Hospital Heidelberg, German Center for Cardiovascular Research (F.S.-H., B.M.).
  • Graw S; Brigham and Women's Hospital, Partners Health Care and Harvard Medical School, Boston, MA (S.K., N.K.L.).
  • Gigli M; Cardiovascular Institute, University of Colorado Anschutz Medical Campus, Aurora (S.G., M.R.G.T., L.M.).
  • Stolfo D; Cardiovascular Department, Azienda Sanitaria Universitaria Integrata, University of Trieste, Italy (M.G., D.S., M.D.F., M.M., G.S.).
  • Dal Ferro M; Cardiovascular Department, Azienda Sanitaria Universitaria Integrata, University of Trieste, Italy (M.G., D.S., M.D.F., M.M., G.S.).
  • Ing AY; Cardiovascular Department, Azienda Sanitaria Universitaria Integrata, University of Trieste, Italy (M.G., D.S., M.D.F., M.M., G.S.).
  • Nussbaum R; Laboratory of Molecular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (A.Y.I., B.F.).
  • Funke B; Invitae, Inc, San Francisco, CA (J.G., R.N.).
  • Wheeler MT; Laboratory of Molecular Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA (A.Y.I., B.F.).
  • Hershberger RE; Division of Cardiovascular Medicine, Department of Medicine (V.N.P., C.C., C.R., M.T.W., E.A.A.), Stanford University School of Medicine, CA.
  • Cook S; Division of Human Genetics, Department of Medicine (R.E.H.), The Ohio State University College of Medicine, Columbus.
  • Steinmetz LM; Division of Cardiovascular Medicine, Department of Medicine (R.E.H.), The Ohio State University College of Medicine, Columbus.
  • Lakdawala NK; National Heart Lung Institute, Imperial College London, UK and National Heart Centre, Singapore (S.C.).
  • Taylor MRG; Department of Genetics (L.M.S., B.M., E.A.A.), Stanford University School of Medicine, CA.
  • Mestroni L; Brigham and Women's Hospital, Partners Health Care and Harvard Medical School, Boston, MA (S.K., N.K.L.).
  • Merlo M; Cardiovascular Institute, University of Colorado Anschutz Medical Campus, Aurora (S.G., M.R.G.T., L.M.).
  • Sinagra G; Cardiovascular Institute, University of Colorado Anschutz Medical Campus, Aurora (S.G., M.R.G.T., L.M.).
  • Semsarian C; Cardiovascular Department, Azienda Sanitaria Universitaria Integrata, University of Trieste, Italy (M.G., D.S., M.D.F., M.M., G.S.).
  • Meder B; Cardiovascular Department, Azienda Sanitaria Universitaria Integrata, University of Trieste, Italy (M.G., D.S., M.D.F., M.M., G.S.).
  • Judge DP; Department of Cardiology, Royal Prince Alfred Hospital and Agnes Ginges Centre for Molecular Cardiology, Centenary Institute, University of Sydney, New South Wales, Australia (J.I., C.S.).
  • Ashley E; Department of Genetics (L.M.S., B.M., E.A.A.), Stanford University School of Medicine, CA.
Circ Heart Fail ; 12(3): e005371, 2019 03.
Article em En | MEDLINE | ID: mdl-30871351
ABSTRACT
Background Variants in the cardiomyocyte-specific RNA splicing factor RBM20 have been linked to familial cardiomyopathy, but the causative genetic architecture and clinical consequences of this disease are incompletely defined. Methods and Results To define the genetic architecture of RBM20 cardiomyopathy, we first established a database of RBM20 variants associated with cardiomyopathy and compared these to variants observed in the general population with respect to their location in the RBM20 coding transcript. We identified 2 regions significantly enriched for cardiomyopathy-associated variants in exons 9 and 11. We then assembled a registry of 74 patients with RBM20 variants from 8 institutions across the world (44 index cases and 30 from cascade testing). This RBM20 patient registry revealed highly prevalent family history of sudden cardiac death (51%) and cardiomyopathy (72%) among index cases and a high prevalence of composite arrhythmias (including atrial fibrillation, nonsustained ventricular tachycardia, implantable cardiac defibrillator discharge, and sudden cardiac arrest, 43%). Patients harboring variants in cardiomyopathy-enriched regions identified by our variant database analysis were enriched for these findings. Further, these characteristics were more prevalent in the RBM20 registry than in large cohorts of patients with dilated cardiomyopathy and TTNtv cardiomyopathy and not significantly different from a cohort of patients with LMNA-associated cardiomyopathy. Conclusions Our data establish RBM20 cardiomyopathy as a highly penetrant and arrhythmogenic cardiomyopathy. These findings underline the importance of arrhythmia surveillance and family screening in this disease and represent the first step in defining the genetic architecture of RBM20 disease causality on a population level.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Arritmias Cardíacas / Proteínas de Ligação a RNA / Cardiomiopatias Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Circ Heart Fail Assunto da revista: ANGIOLOGIA / CARDIOLOGIA Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Canadá

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Arritmias Cardíacas / Proteínas de Ligação a RNA / Cardiomiopatias Tipo de estudo: Etiology_studies / Prognostic_studies / Risk_factors_studies Limite: Humans Idioma: En Revista: Circ Heart Fail Assunto da revista: ANGIOLOGIA / CARDIOLOGIA Ano de publicação: 2019 Tipo de documento: Article País de afiliação: Canadá